RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief

Moderna announces promising efficacy results from mRNA flu vaccine trial

mRNA-1010 demonstrated superior relative vaccine efficacy

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access

Teijin Pharma receives approval for additional indication for XEOMIN in Japan

Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)

Biocon Biologics collaborates with National Cancer Society Malaysia

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

Now approved for both acute and chronic HCV in adults and children aged 3 and above

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme